CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 58 enrolled
Drug / intervention
imatinib mesylate +13 moredrug
Likely dose
Imatinib mesylate given orally (specific dose not stated in provided text)AI-extracted
Key inclusion· 5
  • Unequivocal histologic diagnosis of acute lymphoblastic leukemia (ALL)
  • Philadelphia chromosome-positive disease confirmed by cytogenetics (t(9;22) or 3-way variant) or molecular analysis (RT-PCR or FISH)
  • Complete or partial remission after one course of induction chemotherapy with intensive 4-5 drug regimen on a CALGB or SWOG ALL protocol, with or without prior imatinib
  • Alternatively, complete or partial remission after standard induction regimen (with or without imatinib) without prior cooperative group enrollment; Ph+ positivity may be confirmed outside CALGB/SWOG laboratory
Key exclusion· 2
  • Pregnancy or nursing
  • Inability or unwillingness to use effective contraception for three months after final imatinib dose

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00039377
NCT00039377Phase 2Completed

A Phase II Trial of Sequential Chemotherapy, Imatinib Mesylate (Gleevec, STI571) (NSC # 716051), and Transplantation for Adults With Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia by the CALGB and SWOG

National Cancer Institute (NCI)·interventional·Posted Jan 27, 2003·Updated Nov 24, 2014

In Brief

A Phase 2 clinical trial evaluating imatinib mesylate, methotrexate, and 12 other interventions for Adult Acute Lymphoblastic Leukemia in Remission. Completed, enrolled 58 participants across 97 sites.

Detailed Summary

This phase II trial studies how well giving imatinib mesylate together with chemotherapy and peripheral stem cell transplantation works in treating patients with newly diagnosed acute lymphoblastic leukemia. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. Giving imatinib mesylate together with chemotherapy and peripheral stem cell transplantation may be an effective treatment for acute lymphoblastic leukemia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 27, 2003
Enrollment StartApr 1, 2002
Primary CompletionApr 1, 2012
Study CompletionFeb 1, 2014
TodayJul 2, 2026
Enrollment to primary: 10 yearsPosted 23.4 years ago

Interventions

imatinib mesylatedrug

Given PO

methotrexatedrug

Given IT and IV

vincristine sulfatedrug

Given IV

leucovorin calciumdrug

Given IV and PO

peripheral blood stem cell transplantationprocedure

Undergo PBSCT

autologous hematopoietic stem cell transplantationprocedure

Undergo autologous PBSCT

allogeneic hematopoietic stem cell transplantationprocedure

Undergo allogeneic PBSCT

total-body irradiationradiation

Undergo TBI

tacrolimusdrug

Given IV or PO

filgrastimbiological

Given SC

etoposidedrug

Given IV

cyclophosphamidedrug

Given IV

cytarabinedrug

Given IV

laboratory biomarker analysisother

Correlative studies